clinical trial · NCT03581240

An Intermediate Expanded Use Trial of DFMO

Giselle Sholler·—·available

NeuroblastomaMedulloblastomaTypical Teratoid Rhabdoid TumorEmbryonal Tumor With Abundant Neuropil and True RosettesEpendymoblastomaMedulloepitheliomaeflornithine HCl

brief summary

To provide DFMO in an expanded use setting to subjects with relapsed rare tumors with increased LIN28 expression or MYCN amplification or up regulation of ornithine decarboxylase.

started

—

primary completion

—

completion

—

last updated

Feb 20, 2026

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol